1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

  • April 2017
  • ID: 4897260
  • Format: PDF
  • By Firstword Pharma


This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market

Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI 2017) which demonstrates that efficacy of mepolizumab (Nucala) is not affected by the presence of nasal polyps (which can be indicative of a recalcitrant asthma phenotype), and new data for mepolizumab from the Phase III MUSCA trial is also discussed.

Teva’s presentation at AAAAI 2017 of new data showing that patients with inadequately controlled asthma and aspirin sensitivity received significant clinical improvement in asthmatic symptoms with reslizumab (Cinqiar/Cinqaeor) therapy. Roche/Genentech’s publication of ‘real world’ data from the PROSPERO study involving omalizumab (Xolair), with outcomes reflecting reductions in exacerbation frequency and hospitalisations achieved in earlier controlled clinical trials.

Business Questions:
- In March 2017, GSK presented new data at AAAAI 2017 which demonstrates that mepolizumab’s efficacy is not affected by the presence of nasal polyps, but what is the significance of this data and what impact will it have on prescribing practice?
- At AAAAI 2017, Teva presented data showing that patients with inadequately controlled asthma and aspirin sensitivity received significant improvement in symptoms with reslizumab therapy, but what is the prevalence of aspirin sensitivity and how will the data influence prescribing practice?
- GSK and Teva have both published results from meta-analysis of Phase III studies that prove efficacy of mepolizumab and reslizumab respectively in a subgroup of patients acknowledged to be recalcitrant to standard therapies, but which of these products will be most appealing to prescribers and patients?
- In March 2017, GSK published new data from the Phase III MUSCA study demonstrating mepolizumab’s efficacy in the treatment of severe asthma with an eosinophilic phenotype; primary outcomes, for the first time, included patient reported quality of life improvements. What is the impact of this data and can mepolizumab usage be expected to increase?
- Roche/Genentech published new data from the PROSPERO study that confirms omalizumab’s efficacy in treating allergic asthma in a ‘real world’ setting. How is this data likely to be received amongst prescribers and will omalizumab usage increase?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Nasal Polyps (Nasal Polyposis) - Pipeline Review, H1 2020

  • $ 2000
  • February 2020
  • 107 pages

Nasal Polyps (Nasal Polyposis) - Pipeline Review, H1 2020SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps - Pipeline Review, H1 2020, provides an overview of the Nasal ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on